Thomasville National Bank Reduces Stake in Gilead Sciences, Inc. (NASDAQ:GILD)

Thomasville National Bank cut its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 45.5% during the 1st quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 107,139 shares of the biopharmaceutical company’s stock after selling 89,340 shares during the period. Thomasville National Bank’s holdings in Gilead Sciences were worth $12,005,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently bought and sold shares of GILD. Annis Gardner Whiting Capital Advisors LLC lifted its position in Gilead Sciences by 158.8% during the fourth quarter. Annis Gardner Whiting Capital Advisors LLC now owns 352 shares of the biopharmaceutical company’s stock valued at $33,000 after purchasing an additional 216 shares in the last quarter. Morton Brown Family Wealth LLC purchased a new position in Gilead Sciences during the fourth quarter valued at $35,000. Whipplewood Advisors LLC purchased a new position in Gilead Sciences during the fourth quarter valued at $35,000. Synergy Investment Management LLC purchased a new position in Gilead Sciences during the fourth quarter valued at $40,000. Finally, Lee Danner & Bass Inc. purchased a new position in Gilead Sciences during the fourth quarter valued at $41,000. 83.67% of the stock is currently owned by hedge funds and other institutional investors.

Gilead Sciences Trading Up 2.5%

GILD opened at $112.05 on Friday. The firm has a market cap of $139.38 billion, a P/E ratio of 302.84, a P/E/G ratio of 0.71 and a beta of 0.29. The stock has a 50-day moving average of $105.54 and a 200 day moving average of $102.06. Gilead Sciences, Inc. has a 12 month low of $62.69 and a 12 month high of $119.96. The company has a current ratio of 1.50, a quick ratio of 1.20 and a debt-to-equity ratio of 1.24.

Gilead Sciences (NASDAQ:GILD) last released its earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.81 EPS for the quarter, beating analysts’ consensus estimates of $1.77 by $0.04. The firm had revenue of $6.67 billion for the quarter, compared to analysts’ expectations of $6.77 billion. Gilead Sciences had a return on equity of 31.63% and a net margin of 1.67%. The company’s quarterly revenue was down .3% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($1.32) earnings per share. As a group, research analysts forecast that Gilead Sciences, Inc. will post 7.95 EPS for the current year.

Gilead Sciences Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, June 27th. Stockholders of record on Friday, June 13th will be paid a dividend of $0.79 per share. The ex-dividend date is Friday, June 13th. This represents a $3.16 dividend on an annualized basis and a dividend yield of 2.82%. Gilead Sciences’s dividend payout ratio is 66.53%.

Analyst Ratings Changes

GILD has been the topic of a number of recent analyst reports. Cantor Fitzgerald initiated coverage on Gilead Sciences in a report on Tuesday, April 22nd. They set an “overweight” rating and a $125.00 price target on the stock. DZ Bank raised Gilead Sciences from a “hold” rating to a “buy” rating and set a $108.00 price target on the stock in a report on Thursday, February 13th. Needham & Company LLC reissued a “hold” rating on shares of Gilead Sciences in a report on Wednesday, May 21st. Wells Fargo & Company raised their price target on Gilead Sciences from $120.00 to $140.00 and gave the company an “overweight” rating in a report on Wednesday, March 5th. Finally, JPMorgan Chase & Co. raised their price target on Gilead Sciences from $120.00 to $130.00 and gave the company an “overweight” rating in a report on Thursday, March 27th. Nine equities research analysts have rated the stock with a hold rating, fifteen have given a buy rating and three have given a strong buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $110.55.

Insider Activity

In other news, CEO Daniel Patrick O’day sold 10,000 shares of the company’s stock in a transaction that occurred on Friday, May 30th. The stock was sold at an average price of $110.42, for a total transaction of $1,104,200.00. Following the transaction, the chief executive officer now owns 620,268 shares of the company’s stock, valued at approximately $68,489,992.56. This represents a 1.59% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, insider Johanna Mercier sold 28,000 shares of the business’s stock in a transaction that occurred on Thursday, May 22nd. The shares were sold at an average price of $107.52, for a total value of $3,010,560.00. Following the completion of the sale, the insider now owns 121,152 shares of the company’s stock, valued at $13,026,263.04. The trade was a 18.77% decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 43,000 shares of company stock valued at $4,630,310. 0.27% of the stock is currently owned by insiders.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.